A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin

[1]  M. Steinmetz,et al.  Pironetin Binds Covalently to αCys316 and Perturbs a Major Loop and Helix of α-Tubulin to Inhibit Microtubule Formation. , 2016, Journal of molecular biology.

[2]  J. Naismith,et al.  Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule , 2016, Nature Communications.

[3]  M. Steinmetz,et al.  Control of microtubule organization and dynamics: two ends in the limelight , 2015, Nature Reviews Molecular Cell Biology.

[4]  D. Neri,et al.  Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents. , 2015, Journal of medicinal chemistry.

[5]  R. Chari,et al.  Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies. , 2015, Molecular pharmaceutics.

[6]  A. Waight,et al.  A previously undescribed tubulin binder , 2014, Proceedings of the National Academy of Sciences.

[7]  M. Steinmetz,et al.  A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs , 2014, Proceedings of the National Academy of Sciences.

[8]  R. Chari,et al.  Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. , 2014, Journal of medicinal chemistry.

[9]  R. Borzilleri,et al.  Antibody-drug conjugates: current status and future directions. , 2014, Drug discovery today.

[10]  I. Barasoain,et al.  PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors. , 2014, Biochemical pharmacology.

[11]  Eiman Mukhtar,et al.  Targeting Microtubules by Natural Agents for Cancer Therapy , 2014, Molecular Cancer Therapeutics.

[12]  P. Verma,et al.  Ansamitocin P3 Depolymerizes Microtubules and Induces Apoptosis by Binding to Tubulin at the Vinblastine Site , 2013, PloS one.

[13]  F. Reyes,et al.  Isolation and first total synthesis of PM050489 and PM060184, two new marine anticancer compounds. , 2013, Journal of the American Chemical Society.

[14]  C. Hoogenraad,et al.  Structural basis of tubulin tyrosination by tubulin tyrosine ligase , 2013, The Journal of cell biology.

[15]  M. Steinmetz,et al.  Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents , 2013, Science.

[16]  J. Engel,et al.  Abstract C214: Disorazol Z: A highly cytotoxic natural compound with antitumor properties. , 2011 .

[17]  Richard A. Stanton,et al.  Drugs that target dynamic microtubules: A new molecular perspective , 2011, Medicinal research reviews.

[18]  E. Oroudjev,et al.  Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability , 2010, Molecular Cancer Therapeutics.

[19]  E. Oroudjev,et al.  Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules , 2010, Molecular Cancer Therapeutics.

[20]  Maria Kavallaris,et al.  Microtubules and resistance to tubulin-binding agents , 2010, Nature Reviews Cancer.

[21]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[22]  P. Wipf,et al.  Microtubule Binding and Disruption and Induction of Premature Senescence by Disorazole C1 , 2009, Journal of Pharmacology and Experimental Therapeutics.

[23]  Ronald T. Raines,et al.  Tuning the pK(a) of fluorescein to optimize binding assays. , 2007, Analytical chemistry.

[24]  David C. Richardson,et al.  MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes , 2004, Nucleic Acids Res..

[25]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[26]  B. Bhattacharyya,et al.  Antimicrotubular drugs binding to vinca domain of tubulin , 2003, Molecular and Cellular Biochemistry.

[27]  I. Paterson,et al.  Synthesis and biological evaluation of spongistatin/altohyrtin analogues: E-ring dehydration and C46 side-chain truncation. , 2003, Chemical communications.

[28]  Ronald T. Raines,et al.  Fluorescence assay for the binding of ribonuclease A to the ribonuclease inhibitor protein. , 2002, Analytical biochemistry.

[29]  A. P. Hodgson,et al.  Stereocontrolled Total Synthesis of (+)-Altohyrtin A/Spongistatin 1. , 2001, Angewandte Chemie.

[30]  Y. Engelborghs,et al.  Molecular Recognition of Taxol by Microtubules , 2000, The Journal of Biological Chemistry.

[31]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[32]  J. Wolff,et al.  Localization of the Vinblastine-binding Site on β-Tubulin* , 1996, The Journal of Biological Chemistry.

[33]  Z. Cichacz,et al.  The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain. , 1995, Biochemistry.

[34]  S. Iwasaki,et al.  Rhizoxin binding to tubulin at the maytansine-binding site. , 1987, Biochimica et biophysica acta.

[35]  J. Nishiyama,et al.  Some Properties of Diastereomers formed in the Reactions of N-Ethylmaleimide with Biological Thiols , 1985 .

[36]  Stuart Moss,et al.  Current Status and Future Directions , 2013 .

[37]  J. Díaz,et al.  Characterizing ligand-microtubule binding by competition methods. , 2007, Methods in molecular medicine.

[38]  J. Wolff,et al.  Localization of the vinblastine-binding site on beta-tubulin. , 1996, The Journal of biological chemistry.

[39]  J. Lakowicz.  Principles of fluorescence spectroscopy , 1983 .